E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at Canaccord Genuity MedTech & Diagnostics Forum
November 11, 2021 08:00 ET | electroCore, Inc.
ROCKAWAY, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will be...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Announce Third Quarter 2021 Financial Results on Thursday, November 4th
October 21, 2021 08:00 ET | electroCore, Inc.
ROCKAWAY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Publication Reviewing the Prescribing of gammaCore for the Treatment of Cluster Headache in England
October 20, 2021 08:00 ET | electroCore, Inc.
ROCKAWAY, NJ, Oct. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper entitled...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine
October 14, 2021 08:00 ET | electroCore, Inc.
ROCKAWAY, NJ, Oct. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that the company received an amended Medical...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Provides Business Update and Select Third Quarter 2021 Financial Guidance
October 12, 2021 08:00 ET | electroCore, Inc.
Third quarter 2021 revenue expected to be approximately $1.5 millionNet cash used to fund operations in the third quarter 2021 of approximately $3.5 million ROCKAWAY, NJ, Oct. 12, 2021 (GLOBE...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Acceptance of Motion to Dismiss in the Federal Court Securities Class Action Suit
October 07, 2021 08:00 ET | electroCore, Inc.
ROCKAWAY, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced the granting of the company’s motion to dismiss the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference
September 30, 2021 09:05 ET | electroCore, Inc.
ROCKAWAY, NJ, Sept. 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Open Access and Submission of Manuscript from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients
September 29, 2021 08:00 ET | electroCore, Inc.
ROCKAWAY, NJ, Sept. 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the original author manuscript from the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at Upcoming Investor Conferences
September 23, 2021 08:00 ET | electroCore, Inc.
ROCKAWAY, NJ, Sept. 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Peter Cuneo as Board Chairman 
September 20, 2021 08:00 ET | electroCore, Inc.
ROCKAWAY, NJ, Sept. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Board of Directors has appointed Peter...